Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.36 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.36 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631863 | 1.00 | TP53 (0.38) | TP53HDAC7HDAC8HDAC6HDAC9 | |
| Sulfuric Acid SCHEMBL710697 | 0.92 | TP53 (0.44) | TP53HDAC7HDAC8HDAC6HDAC9 | |
| Sulfuric Acid SCHEMBL11878806 | 0.92 | TP53 (0.44) | TP53HDAC7HDAC8HDAC6HDAC9 | |
| SCHEMBL27411357 | 0.89 | TP53 (0.38) | TP53HDAC7HDAC8HDAC6HDAC9 | |
| SCHEMBL6383889 | 0.82 | TP53 (0.34) | TP53HDAC7HDAC8HDAC6HDAC9 | |
| SCHEMBL28594594 | 0.82 | S1PR2 (0.37) | TP53HDAC1HDAC2CHRM1AKR1A1 | |
| SCHEMBL28703 | 0.82 | — | — | |
| SCHEMBL11142874 | 0.82 | TSHR (0.42) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| 2-Pentanol SCHEMBL10913145 | 0.81 | TP53 (0.41) | TP53HDAC7HDAC8HDAC6HDAC9 | |
| SCHEMBL7704582 | 0.79 | TSHR (0.39) | TP53TSHRCYP3A4NFKB1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238709-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2020-07-01 | — | — | EP | claimed |
| EP-3238709-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-2701684-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2017-06-14 | — | — | EP | claimed |
| US-6927001-B1 | Non-aqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2005-08-09 | — | — | US | claimed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-10665897-B2 | Lithium secondary battery including phosphite additive | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| EP-3315531-A1 | 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2018-05-02 | — | — | EP | disclosed |
| US-20180053967-A1 | LITHIUM SECONDARY BATTERY INCLUDING PHOSPHITE ADDITIVE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-02-22 | — | — | US | disclosed |
| CN-107108727-A | Anti-human VEGF antibodies with exceptionally strong binding affinity for human VEGF-A and cross-reactivity with human VEGF-B | 科学和技术研究全国委员会（科尼特） | 2017-08-29 | — | — | CN | disclosed |
| CN-102762208-A | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | CYLENE PHARMACEUTICALS INC | 2012-10-31 | — | — | CN | disclosed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-1296714-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030026801-A1 | Methods for enhancing antibody-induced cell lysis and treating cancer | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| EP-1280907-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020156033-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2001088116-A9 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS SINAI MEDICAL CENTER (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001088116-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | CHRM1 4179/4885HTR2A 4645/4885HTR2C 4361/4885 |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | CHRM1 3193/4885HTR2A 4318/4885HTR2C 3828/4885 |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | CHRM1 3849/4885HTR2A 4461/4885HTR2C 4037/4885 |
| US-10665897-B2 | Lithium secondary battery including phosphite additive | SCO2, NIBAN2, SLC39A11 | CHRM1 407/4885HTR2A 3839/4885HTR2C 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.